Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates
The proof-of-concept clinical study “Effects of in vivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates” (Rossi et al., American Journal of Transplantation, 2023; DOI 10.1016/j.ajt.2023.02.022) investigated the effects of the CXCR4 antagonist plerixafor, alone or in combination with the proteasome inhibitor bortezomib, on bone marrow plasma cells in HLA-sensitized kidney transplant candidates. Participants received plerixafor monotherapy or combination therapy, and treatment effects on plasma cell mobilization, bone marrow recovery, and transcriptional profiles were assessed. Single-cell RNA sequencing was performed on bone marrow plasma cells collected pre- and post-treatment using 10x Genomics Chromium technology to characterize transcriptional changes associated with therapy. This ENA record contains the raw single-cell RNA sequencing data (FASTQ files) corresponding to the samples analyzed in this publication.